millwallfan
23 Nov 2017
Re: Philips Claude. Also underwater but only from a 48p average so happy to hold as agree potential outweighs current loos level. I have still never had any informed response from anyone on my oft asked questions as to basis of future income generation I.e. One off from machine sales or fee 'per test' - which would obviously be most beneficial. Answers PLEASE anyone in the know !
claude reins
23 Nov 2017
Re: Philips That should push up the SP form today's paltry level then, shouldnt it? Currently Im a loss making holder! My strong buy is more in hope than expectation, but I do think that this company is highly underrated given the terrific value benefits of the technology.
millwallfan
23 Nov 2017
Re: Philips And introduces a risk of a Philips takeover. Watch for stakebuilding as Philips could buy angle from petty cash
autpaxautbellum
23 Nov 2017
Philips This gives more traction to the technology and its wide adoption.
millwallfan
07 Nov 2017
Re: Good news about heavyweifght investo... sorry no specific reference just automatically assumed this far down the road they would have fully protected their position otherwise the company could be worthless e.g. Through industrial espionage / disgruntled ex employee etc.
claude reins
06 Nov 2017
Re: Good news about heavyweifght investo... Perhaps Im behind the times. I cannot remember them saying they had. I can remember some little time ago that they werw working towards patenting their approach, whatevr that means. Im an economist, not a scientist! If you have a particular reference in mind, please let me know.
millwallfan
06 Nov 2017
Re: Good news about heavyweifght investors Hi CR. I thought thethe patents were all in place?
claude reins
06 Nov 2017
Good news about heavyweifght investors ..increasing their holdings as a result of the M&A activity recently surrounding AGL. Today, Fidelity, Jupiter and L&G all showing signficant increases in their % holdings. Shows great confidence in the company going forward.Apart from upwards, where is this company going? It wouldnt surprise me if in the coming monthd, particularly if they are able to continue their what is really a fantastic record of medical achievement across a whole spectrum of cancers and of course get patent protection, then they could go through the roof on their own, with or without significant add=ons like the recent one, or be taken over at a significant premium by a major.Patience required as always, but really on the way this time. All IMHO.
millwallfan
18 Oct 2017
Re: Im quite excited thiugh investors ar... Thanks CR. I do think understanding if it will be 'one off' sales revenue or a fee 'per test' - the latter which would obviously be highly lucrative once the number of hospitals/clinics wishing to use the technology has peaked.
claude reins
18 Oct 2017
Re: Im quite excited thiugh investors ar... Yes there is a reference in the finals to the numbers of machines and the number of tests, comparing 17 and 16 but little effect on revenue. Perhaps that is a question we can put to the CEO and also Finncap who have a key objective to raise the profile of the company, dont they, to prove their worth. I will give it a thunk - deep one!
millwallfan
18 Oct 2017
Re: Im quite excited thiugh investors are im... I share your optimism in the main and am also down. but would really like to know the answers to the questions I raised on 27 July (also previously) which no-one has ever responded.
claude reins
17 Oct 2017
Im quite excited thiugh investors are impatient I am a shaeholder and am running at a loss, so some of the things I am saying must be read in that context. He would say that wouldnt he?In fact there is a lot of good news going on around this compnay right now.1. They get into bed with Quiagen, which company not only has many customers/contacts and is very much bigger than AGL, but also AGL's star system fits well into their own programme of offerings to the medical world.2. They get a much bigger name in the NOMAD Finncap and they should do a better job of puttingAGL out th.3.AGL continues to build up a whole host of supporters in N America and Europe in the medical world, both in terms of actual and also comparable performance. This latest Muenster result is testimony to that. These run across a whole range of prolem areas (this one is renal) though the major target areas have been reiterated as breast cancer and prostate cancer.4.The cash raising gives them sufficient to make a significant acquisition which give them extra vertial coverage - what in normal industry we would vertical integration - to offer a suite including several levels of the process to help practitioners in this huge opportunity field - and I mean huge.5.The extra cash also underpins the cost of the route to market, and should see them through a fair period - how long I dont know. Will they need more? Possibly, though this raising was at a very small discount to the market price.Anyone want to disagree, or even agree? Anyone want to add any queries/question marks (or even answers to such queries/questions) that I havent mentioned?All additionas to a sensible BB welcome!
autpaxautbellum
17 Oct 2017
RNS today Adequate funding, yet more technical verification of superiority over existing systemsThis must be set for an upward path.
millwallfan
09 Oct 2017
RNS Surely this latest information provides even greater market potential for the product?? I posed a question sometime ago asking if anyone knew the basis of future income generation I.e. Is it 'one off' income per testing machine sold or is it much more lucrative income 'per test' performed - or the icing on the case both. Any informed view please
niceandsimple
05 Oct 2017
Live in hope [link]
